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CObjective: The joint impact of cognitive, functional, and behavioral
statuses must be measured when exploring the impact of new drugs on
Alzheimer’s disease (AD) costs. There are very few recent studies of AD
costs by all dimensions of disease severity. Our objective was to im-
prove estimation of the relationship between AD severity and costs of
AD care by using more comprehensive AD data severity and a large
sample size. Methods: Participants were community-dwelling AD pa-
tients recruited between 2003 and 2005 and followed annually during a
2-year period in 50 French memory clinics. We used the Resource Use
in Dementia questionnaire to estimate costs from a societal perspec-
tive. We explored the presence of potential endogeneity bias by using
instrumental variable regressions. Results: Cognitive declines im- O
Pari
al So
oi:10.1016/j.jval.2012.02.003acted informal costs more than medical and nonmedical costs, while
unctional declines impacted nonmedical costs more than medical and
nformal costs. Both cognitive and function declines increased the total
osts of care. We found that the endogeneity of these variables led to a
arge underestimation of their impact of AD severity on costs.
onclusion: Potential endogeneity should be controlled for to pre-
ent biased estimations of the impact of AD severity measures on
osts.
eywords: Alzheimer’s disease, community-dwelling, cost, endogene-
ty, severity.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
A large focus of Alzheimer’s disease (AD) research has been to
explore how disease severity influences costs of care [1]. The Eu-
ropean Medicine Agency has clearly stated in its guidance on the
development of new drugs for AD that the joint impact of cogni-
tive, functional, and behavioral statuses must be measured when
exploring the impact of new drugs on AD costs. In pharmacoeco-
nomic evaluations that occur during phase III drug development,
cost-effectiveness analyses are used to estimate long-term bene-
fits associated with the use of therapeutic innovations [2–4] or
clinical interventions [5–7]. For health technology assessment and
coverage decision, being able to provide robust and unbiased esti-
mates of the relationship between AD severity and costs is a major
issue [8].
Current evidence of the relationship between AD severity mea-
sures and costs, however, is limited by important data limitations
identified in previous research. There are very few recent studies
of AD costs by all dimensions of disease severity. After almost two
decades of research exploring the relationship between cognitive,
functional, and behavioral declines and costs, two recent litera-
ture reviews underline the need for more comprehensive data
supporting future economic evaluations of AD therapies.
Mauskopf et al. [8] published the most recent review of the
literature on the subject exploring the strength of the relationship
between AD severity measures and costs among 29 articles pub-
* Address correspondence to: Thomas Rapp, LIRAES, University of
E-mail: thomas.rapp@parisdescartes.fr.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.lished between 1993 and 2008. This review shows that most arti-
cles had important sample limitations: only six articles had large
sample sizes (1000), and only five articles used longitudinal data.
These sample limitations can be important, because reduced sam-
ple size and shortened time of the study reduce the probability of
observing meaningful pharmacoeconomic outcome [9]. The AD
severity information provided in most published articles was not
comprehensive. While AD severity has multiple components (cog-
nition, function, behavioral), only five articles reviewed by Maus-
kopf and colleagues controlled for more than two measures of AD
severity. While informal care has been shown to represent more
than half of total costs in dementia [10,11], only 14 of the reviewed
studies included both direct and indirect costs.
Important limitations have also been identified in a literature
review by Jonsson and Wimo [11]. Among 16 reviewed articles
exploring factors associated with the cost of care in AD, only 12
articles had patients with a diagnosis of probable AD, only 9 arti-
cles focused on patients living in the community, and only 9 arti-
cles were not cross-sectional [11]. In their conclusion, Jonsson and
Wimo provided three main recommendations to improve future
studies exploring factors associated with costs of AD: 1) use of a
validated instrument for the assessment of informal care, 2) mea-
surement of disease severity by using cognitive, functional, and
behavioral disturbances, and 3) enhancement in sample size.
The statistical methods used in prior research also have impor-
tant limitations. In particular, no article explored the influence of
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413V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 1 2 – 4 1 9potential endogeneity biases that could be important in studies
exploring the impact of AD severity on costs [8]. Endogeneity
concerns may arise with clinical characteristics that both in-
crease cost and worsen cognition. Endogeneity concerns are
raised when one or more independent variables are correlated
with the error term and/or when there is a simultaneous deter-
mination of costs and the independent variable of interest. For
instance, endogeneity can be suspected with the relationship
between cognitive decline and costs. Cognitive decline is asso-
ciated with increased costs of care, but patients with largest
care expenditures are often those whose decline is highest. Fail-
ing to address endogeneity bias could lead to misinterpreting
the relationship between these variables; for example, the rela-
tionship between cognitive impairment and costs cannot be
precisely measured without using instrumental variables (IVs).
Such variables are correlated with the endogenous variable but
are uncorrelated with the error terms.
Finally, most studies could have underestimated informal
costs, especially when surveillance was not included in informal
care measures [12–14]. Many studies may face specification errors
because they did not control for patient and caregivers’ character-
istics, such as age, gender, and comorbidities.
There is need for a comprehensive assessment of direct and
indirect resources utilization and for research with a greater level
of evidence regarding the relationship between AD severity and
costs [9]. The objective of this article was to improve estimation of
the relationship between changes in AD severity measures and
costs of care by using more comprehensive data and improved
statistical methodologies.
We used longitudinal data of elderly patients diagnosed with
AD that provide comprehensive information dealing with patients
and caregivers’ characteristics. Our analyses focused on the
French context, where community-dwelling patients have access
to several medical and nonmedical services designed to support
their needs. In France, patients living in the community can also
benefit from several sources of public financial support, depend-
ing on their dependence level [15].
Methods
Sample
The sample was drawn from the PLASA (Plan de Soin et d’Aide
spécifique à la maladie d’Alzheimer) study, a large randomized trial
designed to evaluate the effect of a multicomponent specific care
and assistance plan in AD primarily looking at change in func-
tional capacity. This study has been described in previous publi-
Table 1 – Units costs calculations.
Item Cost
Institutionalization €81.17 per day KPM
Inpatient hospitalization €4670.56 per visit Fren
Outpatient hospitalization €481.67 per visit Fren
Physiotherapy visit €36.94 per visit Fren
Speech rehabilitation visit €50.10 per visit Fren
Medication unit €58.71–€97.13 per box Thé
Physician visit €22 per visit Fren
Informal care €17.29 per hour Fren
Home help care €7.86 per hour Fren
Nurse visit €13.36 per hour Fren
Day surveillance €13 per hour Aut
Night surveillance €16 per hour Aut
Alarm services use €7.20 per month Aut
Day care €10.67 per visit Authors’cations [16,17]. Our sample consisted of 1131 patients diagnosed
with mild to moderate AD. Patients were recruited between June
2003 and July 2005 from 50 French memory clinics. Inclusion cri-
teria required that patients lived in the community, had a primary
informal caregiver (self-reported), and had a Mini-Mental State
Examination [18] (MMSE) score between 12 (severe) and 26 (mod-
rate).
Data were collected at three time points: the baseline visit,
he year 1 visit, and the year 2 visit. Of the 1131 patients in our
ample, 175 (15.47%) became institutionalized during the study
eriod.
Measures
Cost variables
Costs were calculated from the societal perspective for each type
of resource. We had four dependent variables of interest measur-
ing informal, nonmedical, medical, and total costs for the month
prior to each visit. Informal costs represented costs associated
with surveillance, activities of daily living (ADL), and instrumental
ADL. Nonmedical costs included costs associated with the use of
day care, alarm services, home help, and day/night surveillance.
Medical costs included costs associated with inpatient and outpa-
tient hospital visits, physician visits, speech therapist visits, phys-
ical therapist visits, nurse visits, and medication use. Total costs
per month were calculated by summing informal, nonmedical,
and medical care costs for each patient.
We calculated resource utilization and costs for the month
prior to the visit (baseline, year 1, and year 2) by using the Re-
source Use in Dementia 2.0 questionnaire [12,13,19,20]. The Re-
source Use in Dementia questionnaire measures all inpatient
and outpatient costs that can be attributed to AD care. We con-
trolled for several patient and caregivers’ characteristics, such
as age and gender, which have been shown to influence costs
[1,21–28].
Unit costs were collected by using various data sources, and
estimated in FY07 euros by using the French consumer price in-
dex. Cost items, unit costs, and sources are reported in Table 1.
Hospitalization costs (nursing, care, pharmacy, diagnostic tests,
laboratory tests, staff, general equipment, administration, secu-
rity, central supply, dietetics, social services) were assessed at the
University Hospital of Toulouse by using the French diagnosis-
related groups and the national unit cost scale. Hospitalization
unit costs were identified for patients with AD diagnosis. Medical
procedures performed outside the hospital were valued according
to the French Social Health Insurance tariffs. Institutionalization
costs included many components such a staff, catering, and laun-
Source
ues and Insights, Observatoire maison retraite 2010
iagnosis-related groups and the national unit cost scale 2003–2007
iagnosis-related groups and the national unit cost scale 2003–2007
iagnosis-related groups and the national unit cost scale 2003–2007
iagnosis-related groups and the national unit cost scale 2003–2007
e. Thériatique drug data 2010
cial Health Insurance AMELI.FR. L’assurance maladie en ligne 2010
ational Institute of Statistics and Economic Studies 2010
ational Institute of Statistics and Economic Studies 2010
ational Institute of Statistics and Economic Studies 2010
calculations based on tariffs provided by a pool of private providers
calculations based on tariffs provided by a pool of private providers
calculations based on tariffs provided by a pool of private providersG Iss
ch d
ch d
ch d
ch d
riaqu
ch So
ch N
ch N
ch N
hors’
hors’
hors’calculations based on tariffs provided by a pool of private providers
(
d
m
j
t
d
m
b
h
i
d
m
p
m
m
n
n
w
c
f
i
p
A
f
(
a
i
i
3
c
t
u
m
c
v
i
p
l
s
t
p
r
t
c
s
m
c
s
c
t
s
t
v
w
f
a
i
w
t
t
i
f
i
t
414 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 1 2 – 4 1 9dry services costs. Medication unit costs were assessed by using
the commercial price of AD drugs from public data. Physician vis-
its were valued according to the appropriate reimbursement tar-
iffs used by the French Social Health Insurance. To estimate infor-
mal costs, we used the replacement wage method and assumed
that the unit cost was equal to the average hourly wage in French
private industries.
Clinical variables
Cognitive status was measured with the MMSE, a continuous
variable ranging from 0 to 30; higher scores indicate better cog-
nitive function. We controlled for a comorbidity count measure
that included conditions that have been found to be highly prev-
alent in AD— diabetes, hypertension, coronary heart disease,
depression, and epilepsy [29]—and other prevalent conditions
such as hypercholesterolemia, degenerative arthritis, sight
troubles, and audition troubles. Other indicators of AD severity
were measured for only half the sample, reducing the number of
observations for these variables. Functional status was mea-
sured with the Katz ADL scale. We measured whether the pa-
tient was dependent, partially autonomous, or autonomous for
the following ADL: bathing, dressing, toileting, transferring,
continence, and feeding [30,31]. For each ADL component, a
score of 0 was given when the patient was dependent, a score of
0.5 was given when the patient was partially autonomous, and a
score of 1 was given if the patient was autonomous. In conse-
quence, most dependent patients had a score of 0 while patients
with full function had a score of 6. The Neuropsychiatric Inven-
tory (NPI) was used to estimate both the severity and frequency
of a wide range of behavioral reactions including agitation, de-
pression, nighttime behavior disturbances, appetite and eating
abnormalities, dysphoria, anxiety, apathy, irritability, aberrant
motor behavior, delusion, hallucination, and disinhibition
[32,33]. The total NPI score may range from 0 to 144, and it rated
both the frequency and the recurrence of abnormal behaviors.
Higher scores indicated greater impairment.
Sociodemographic variables
We controlled for additional variables that were used in previous
research: patients’ age at baseline [14,21–23,27], gender [21–23,27],
and informal caregivers’ gender [14]. The Zarit Burden Interview
ZBI) 22-item version was used to describe caregivers’ health con-
ition, psychological well-being, finances, and social life. The ZBI
ay range from 0 to 88, and informal caregivers with greater sub-
ective burden had higher scores [34]. We also controlled for pa-
ients’ education level (high school education) and time since AD
iagnosis.
Analysis
We used nonparametric Wilcoxon rank-sum tests to estimate
statistical differences between groups of patients’ characteris-
tics; for example, we tested the hypothesis that two groups were
from populations with the same distribution. Groups were de-
fined by samples mean for each continuous variable.
For multivariable cost analyses, we decided to log-transform
our dependent variables, which were highly skewed. We ran
mixed-effects models to allow the effect of time to vary across
patients. Indeed, it was possible that different patients’ costs of
care grew at different rates over time. We first included a ran-
dom intercept to measure the random deviation of each pa-
tient’s mean cost from the overall mean (between-patient vari-
ance) and the random deviation of costs from each patient’s
mean cost (within-patient variance). In other words, the be-
tween-patient variance component was specific to each patient
and constant over time, while the within-patient variance com-
ponent was specific to each patient at each visit. Second, we 1estimated models with a random intercept and a random coef-
ficient for time, to allow the effect of that variable to vary be-
tween patients. Likelihood-ratio tests comparing the random-
intercept models and the random-coefficient models were
significant (P  0.01), indicating that the random-coefficient
odels fitted better than the random-intercept models.
Mixed-effects models have several advantages: they use
oth fixed and random effects in the same analysis, they flexibly
andle intrasubject correlation and provide correct estimators
n the presence of the correlated errors that may arise from a
ata hierarchy, they use all the available information (repeated
easures), and they are robust to missing at random data. The
attern of missing data allowed us to assume that values were
issing at random, for example, that the probability of having a
issing value at one visit depended on previous occasions but
ot on the values that would have been observed if they were
ot missing. By using maximum likelihood estimations, we
ere able to run our analyses on patients who had at least one
omplete assessment over the study period. Models controlling
or MMSE and sociodemographic variables were run by using
nformation from 920 patients (1554 observations) and from 957
atients in the analyses that included all institutionalizations.
nalyses that controlled for ADL, NPI, and ZBI used information
rom 447 patients, for 757 observations over the 2-year period
half of our sample received ADL, NPI, and ZBI assessments),
nd 481 patients in the analyses that included all institutional-
zations. We explored the impact of AD severity contenders on
nformal care costs (models 1 and 2), medical care costs (models
and 4), nonmedical care costs (models 5 and 6), and total care
osts (models 7, 8, 9, and 10).
We explored the presence of potential endogeneity biases in
he relationship between MMSE, ADL, NPI, ZBI and AD costs by
sing random-effects regressions with IVs. Valid instruments
ust be associated with the endogenous variable but not asso-
iated with the error term [35]. Our instruments were the lagged
alue of total costs, patients’ level of education, and a categor-
cal variable measuring whether another informal caregiver
rovided help rarely, sometimes, or always. The choice of a
agged economic variable as an instrument for AD severity mea-
ures was motivated by the assumption that the past value of
otal costs may not be systematically correlated with unex-
ected changes in current care consumption, for example, cur-
ent total cost. Also, previous research has provided evidence
hat patients’ education was associated with AD patients’ de-
line [36], while a comparison of care use by patients’ years of
chooling did not provide significant results [28]. Finally, infor-
al care time provided by caregivers other than the primary
aregiver has been shown to be small [20], while it can be as-
umed that its influence on patients’ decline is important. We
hecked that our instruments were not correlated with the error
erms by using the Sargan-Hansen test of overidentifying re-
trictions [37]. We tested for weak identification by comparing
he Cragg-Donald F statistic [38] with Stock and Yogo’s critical
alues [39]. To explore the effect of endogeneity on our results,
e also ran a random-effect model without the IVs.
Because of missing values, we had institutional costs only
or three institutionalized patients. We, therefore, assumed in
dditional analyses that patients with permanent institutional-
zation did not receive any care other than the care provided
ithin the institution. In other words, we assumed that for
hese patients, the total cost of care was equal to the cost of
heir institutional stay. Indeed, previous research provided ev-
dence that institutionalization causes a shift from informal to
ormal caregiving [40]. That assumption allowed us to estimate
nstitutional costs for all 175 patients with long-term institu-
ionalization in our analyses. All analyses were run with Stata
1.1 (StataCorp, College Station, TX).
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Descriptive statistics of patients’ sociodemographic and clinical
characteristics at baseline are provided in Table 2. The mean
MMSE score was 19.69 (4.02), mean ADL score at baseline was
.42 (0.91), mean NPI score at baseline was 17.12 (15.09), and
ean ZBI at baseline was 23.38 (15.20).
Table 3 presents data on informal, nonmedical, medical, and
otal costs for the month prior to the baseline visit, according to
atients’ characteristics. Patients with worse cognitive function-
ng had greater costs, except for medical costs for which the Wil-
oxon test was not significant. Compared with patients with an
MSE score of more than 20 (mean sample value), patients with
n MMSE score of 20 or less had greater informal costs (€1794.45 vs.
2792.02, respectively; P 0.01), greater nonmedical costs (€178.36
s. €219.02, respectively; P 0.05), and greater total costs (€2377.33
vs. €3379.31, respectively; P  0.01). Compared with patients with
ADL scores of more than 4, patients with ADL scores of 4 or less
had greater informal costs (€1612.79 vs. €5398.45, respectively; P
0.01), nonmedical costs (€149.63 vs. €500.14, respectively; P 0.01),
medical costs (€340.56 vs. €788.80, respectively; P 0.01), and total
Table 2 – Characteristics of the patients at baseline.
Characteristics Mean
Patient’s age (y) 79.77
Female patient (vs. male) 0.68
Baccalaureate (yes vs. no) 0.14
Mini-Mental State Examination 19.69
History of diagnosis 1.35
Number of comorbidities 2.32
Female informal caregiver (vs. male) 0.61
Activities of daily living 5.42
Neuropsychiatric Inventory 17.12
Zarit Burden Inventory 23.38
Notes. Statistics provided for age, gender, baccalaureate, Mini-Ment
were obtained from the sample of 815 patients who had nonmissing
psychiatric Inventory, and Zarit Burden Inventory were obtained from
other covariates (Mini-Mental State Examination, age, gender, educa
ties), mean values were similar to values found in the larger sample
Table 3 – Informal, nonmedical, medical, and total costs of
Severity measure Informal cost
Mean SD
Mini-Mental State Examination score
20 2792.02* 3683.85
20 1794.45 2927.92
Activities of daily living score
4 5398.45* 4555.41
4 1612.79 2602.05
Neuropsychiatric Inventory score
17 1688.93* 2798.45
17 2746.16 3616.15
Zarit Burden Interview score
23 1408.99* 2549.44
23 2955.45 3644.64
Notes. Costs provided for Mini-Mental State Examination were obta
baseline visit. Costs reported for activities of daily living, Neuropsy
subsample of 447 patients with nonmissing values at baseline.
* Significant at the 1% level.
† Significant at the 5% level.costs (€2107.44 vs. €6687.40, respectively; P  0.01). Worse NPI and
ZBI scores were associated with greater informal and total costs
(P  0.01).
Figure 1 presents cost data estimated at each visit. The mean
cost of AD per month was €2918 at baseline, €3112 at year 1, and
€4101 at year 2. Informal cost was the largest cost component
per month, and its importance in total costs increased over
time: €2334 at baseline, €2510 at year 1, and €3373 at year 2.
Table 4 presents regression results obtained for informal and
formal costs. Because the dependent variables were log-trans-
formed, we interpreted marginal effects as follows: for a unit
change in MMSE and ADL score, costs increased by 100% of the
coefficient estimate for these two continuous variables [27]. In
model 1, a decrease in cognitive decline was associated with an
8.61% increase in informal costs (P  0.01). In model 2, the im-
pact of MMSE on informal costs was lower (4.79%; P  0.01). A
marginal loss in ADL was associated with a 25.40% increase in
informal costs, and a marginal increase in ZBI was associated
with a 4.33% increase in informal costs. In model 3, a marginal
decrease in MMSE score was associated with a 0.63% increase in
medical costs (P  0.05), and a marginal loss of one ADL was
SD Minimum Maximum
5.74 56 97
— — —
— — —
4.02 12 26
1.65 0 13
1.45 0 8
— — —
0.91 1 6
15.09 0 84
15.20 0 76
te Examination, history of diagnosis, and number of comorbidities
es in the baseline visit. Statistics for activities of daily living, Neuro-
ubsample of 379 patients with nonmissing values at baseline. For all
history of Alzheimer’s disease diagnosis, and number of comorbidi-
patients.
at baseline by severity measure.
medical cost Medical cost Total cost
an SD Mean SD Mean SD
.02† 806.57 364.91 1162.23 3379.31* 4138.33
.36 647.59 404.50 1309.98 2377.33 3380.66
.14* 1454.63 788.80* 1799.24 6687.40* 5562.14
.63 592.71 340.56 1179.49 2107.44 2981.41
.71 829.01 376.90 1187.16 2260.54* 3474.64
.38 631.31 428.65 1422.83 3375.67 4015.60
.43† 779.90 399.74 1247.99 1994.17* 3362.73
.04 737.03 391.49 1320.40 3558.95 3975.71
from the sample of 815 patients who had nonmissing values in the
ric Inventory, and Zarit Burden Interview were obtained from theal Sta
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416 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 1 2 – 4 1 9associated with a 36.44% increase in medical costs (P  0.01). In
odel 5, a marginal decrease in MMSE score was associated
ith a 5.58% increase in nonmedical costs (P  0.01). In model 6,
marginal loss in ADL was associated with a 52.31% increase in
onmedical costs (P 0.01). In model 7, a unit decrease in MMSE
core had an 8.01% impact on total costs (P  0.01). In model 8,
arginal losses in ADL, NPI, and NBI scores were, respectively,
ssociated with 28.65%, 0.62%, and 2.10% increases in total costs
P 0.01). In model 9, a unit decrease in MMSE score had a 6.40%
mpact on total costs (P  0.01). This effect of MMSE was de-
reased in model 9, and ADL, NPI, and NBI had significant im-
acts on total costs of care.
In Table 5, we found evidence of endogeneity in the relation-
ship between MMSE and total costs. Lagged variables were ac-
ceptable instruments in models 11 and 13, for example, not
correlated with the error term, because the overidentification
test of all instruments was rejected (P  0.3895 and P  0.6091,
respectively). When comparing models 11 and 12, we found that
the endogeneity bias led to a large underestimation of the in-
fluence of MMSE on total costs. In model 11, a marginal decrease
in MMSE score was associated with a 29.30% increase in the total
cost of care compared with a 7.00% increase in the model that
did not control for endogeneity (model 12). When controlling for
endogeneity in model 13, marginal losses of cognitive, func-
tional, and behavioral statuses and ZBI were no longer signifi-
cant, probably because of a sample size issue (N  226). We
observed, however, large differences between coefficients in
models 13 and 14. Assuming that the total costs were equal to
the costs of institutionalization for patients with long-term
stays, we ran previous regressions in larger samples: 481 pa-
tients in models 15 and 16 and 259 patients in models 17 and 18.
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Fig. 1 – The mean cost of Alzheimer’s disease. This figure
represents mean informal, nonmedical, and medical costs
per patient for the month prior to each visit. Informal costs
represented costs associated with surveillance, activities of
daily living, and instrumental activities of daily living.
Nonmedical costs included costs associated with the use of
day care, alarm services, home help, and day/night
surveillance. Medical costs included costs associated with
inpatient and outpatient hospital visits, physician visits,
speech therapist visits, physical therapist visits, nurse
visits, and medication use. Baseline costs were estimated
among 815 patients, year 1 costs were estimated among
434 patients, and year 2 costs were estimated among 305
patients. The mean total cost of Alzheimer’s disease per
month was €2918 at baseline, €3112 at year 1, and €4101 at
ear 2.We obtained similar results.T V M A N Z N N se n A * † ‡
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To our knowledge, this study is the first to explore the joint
impact of cognitive, functional, and behavioral impairments
and caregivers’ burden on costs of care for patients with AD.
This comprehensive approach confirmed the need to control for
all dimensions of AD severity in cost studies. The results of our
study confirmed those of previous studies. For patients with
less severe AD, informal care is the most expensive component
of costs [11,22,24,28]. Previous research found that when AD
patients are not institutionalized, informal caregiving would
represent more than 70% of total costs of caring [24], which is
similar to our estimates. Other studies provided evidence that
MMSE was a strong determinant of informal care [41]. By using
data from the Predictors Study, Zhu and colleagues provided
evidence that function losses were associated with greater in-
formal, medical, and nonmedical costs [21–24,28].
Our study addressed several weaknesses identified in pub-
lished articles dealing with the cost of AD [1,11,42]. We used lon-
gitudinal data and a large sample of patients living in the commu-
nity while most studies have a small sample, which raises
generalizability concerns. Our data was collected in 50 memory
clinics nationwide and may be generalized to the whole French
community-dwelling population. We used a validated question-
naire to measure patients’ use of care. The Resource Use in De-
mentia 2.0 questionnaire is the most comprehensive version of
the questionnaire, underlining the value of our data for studies
exploring costs of care in AD. Also, we provided a clear classifica-
tion of resources that separated three cost components: medical,
nonmedical, and informal care. When possible, information on
unit costs was specific to AD patients. Finally, this study was the
first to explore the impact of various domains of AD severity on
costs of care in France.
Our results highlight the need to deal with methodological
considerations that were neglected in studies exploring factors
associated with increase in AD cost of care. Indeed, this study is
the first to provide evidence of an endogeneity bias in the rela-
tionship between cognitive decline and costs, leading to a large
underestimation of the impact of MMSE on costs. The longitu-
dinal nature of our data provided a unique opportunity to use
lagged variables as IVs. Lagged values of total costs were found
to be relevant IVs, which were highly correlated with MMSE but
not correlated with the error term. Finding satisfactory IVs is
generally difficult, but in our study lagged variables were found
to be strong instruments, underlining the important advantage
of using longitudinal data.
There are several limitations in our study. The main limita-
tion came from the fact that we worked on a reduced sample.
The choice of creating cost variables that included many items
led us to have very detailed cost measures, but also required
that we deal with a large number of missing values. Of the 1131
recruited patients, only 959 were included in the analyses that
controlled for MMSE and sociodemographic variables. Finally,
ADL, NPI, and ZBI assessments were provided for only half of
our sample, which constrained us to explore the joint impact of
cognitive, functional, and behavioral statuses in a subsample
of 470 patients. Our third objective (using a larger sample) was
not fully achieved, although our sample was still larger than
other comparable cohorts such as the Predictors Study. Finally,
including institutionalized patients in estimations of compo-
nent costs introduced substantial changes in the distribution of
the dependent variables. The concentrations of zeroes could
raise sample selection problems. Our results must be inter-
preted considering that issue.
Pharmacoeconomic models for new drugs may want to use
dependence as a composite measure. Unfortunately, the PLASA
study protocol did not include such a measure. Our analyses,
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418 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 1 2 – 4 1 9however, controlled for several AD severity measures (func-
tional, cognitive, and behavioral) and for a variable measuring
the number of patients’ comorbidities. As such, our analyses
controlled for the most important dimensions of patients’ de-
pendence. To our knowledge, our costs analyses are the first to
control for a variable measuring the burden on informal care-
givers (Zarit), which is quite important in AD costs analyses,
because informal caregiving time is a major cost component.
Finally, other limitations came from our cost estimations. First,
they were restricted to the month prior to the visit; we were not
able to determine costs that occurred between visits. Second,
unit costs that were estimated by using tariffs only could lead to
estimation biases for the total cost of home health care. Third,
informal care estimations focused on care provided by only the
primary caregiver, although some patients had additional infor-
mal caregivers.
In conclusion, the use of more comprehensive data confirmed
the strong correlations between MMSE, ADL, comorbidities, and
costs. We found a greater level of evidence of the relationship
between AD severity and costs. The most important predictors of
costs were functional and cognitive declines. We found that the
impact of MMSE was reduced when controlling for various con-
tenders of AD severity. The impact of ADL on various costs com-
ponents was very important and contributed to a reduced influ-
ence of MMSE on costs. The construction of a comprehensive
measure of AD severity should use different weights for each com-
ponent. Finally, we found the evidence of endogeneity within the
relationship between MMSE and costs. Failing to control for endo-
geneity could lead to a large underestimation of the impact of
MMSE on costs. Thus, controlling for endogeneity is a crucial issue
for pharmacoeconomic models that explore the value of a new AD
drug. We recommend the use of lagged economic variables to in-
strument endogenous variables. Further research should explore
endogeneity, which could occur in analyses controlling for com-
posite dependence measures that gather functional, cognitive,
and behavioral impairments.
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